IXICO has announced two significant contract wins with a combined value of approximately £1.3m, to be recognised over multi-year timelines. The first is a collaboration with a major pharmaceutical company to provide trial management and imaging analysis for a Phase 1 Alzheimer’s Disease (AD) clinical trial. This agreement spans around three and a half years and reinforces Alzheimer’s as a core indication for IXICO’s business. The second win, with a US-based biotechnology company, involves high-q ....
